ArticleFrontiers in public health2025
Ten-year survival in early-stage breast cancer patients in a comprehensive breast cancer care program in India.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic enzymes and immune receptors as emerging checkpoints in breast cancer: mechanisms, clinical trials, and therapeutic implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer accounted for 21.9% of all cancer deaths among women in India in 2020. Fifty seven percent of the breast cancers in India are detected at advanced stages. The lack of adequate resources for diagnosis and treatment adds to the delay and reduces survival. The clinical stage at diagnosis is the most important prognostic factor. Increased cancer awareness, early diagnosis, and affordable and accessible treatment facilities have been recommended for clinical downstaging and improved survival in low- and middle-income countries including India. We implemented a comprehensive breast care program based on these recommendations. This study explores the long-term survival outcomes of patients diagnosed with early-stage breast cancer (EBC) in an early detection program within a universal health coverage (UHC) scheme. Methods: This is a cohort study of women diagnosed with early-stage breast cancer under the UHC scheme between 2008 and 2018. The follow-up was done through electronic medical records, in-person clinic visits, and telephone calls. The primary outcomes were 5- and 10-year overall survival and disease-free survival. Results: A total of 185 patients who presented with EBC were recruited among 254 incident breast cancer cases throughout the study period (72.8%). The average overall survival was 123 months. Five-year overall and disease-free survival were 85.2 and 84.6%, respectively. Ten-year overall and disease-free survival were 79.0 and 76.2%, respectively. Discussion: This study underscores the importance of early detection in breast cancer. It also demonstrates that 5- and 10-year survival rates better than those reported in Indian cancer registries are achievable through comprehensive cancer care and UHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.